Michèle Barzach
Corporate Officer/Principal at International AIDS Vaccine Initiative, Inc.
Michèle Barzach active positions
| Companies | Position | Start | End |
|---|---|---|---|
International AIDS Vaccine Initiative, Inc.
 International AIDS Vaccine Initiative, Inc. Pharmaceuticals: MajorHealth Technology International AIDS Vaccine Initiative, Inc. researches and develops to prevent HIV infection and AIDS. It researches and develops vaccine candidates, conducts policy analyses, and serves as an advocate for the field with offices in Africa, India, and Europe. The firm's HIV research and development focuses on three strategies: the design of vaccine immunogens capable of inducing specialized proteins known as broadly neutralizing antibodies, the optimization and development of these antibodies as prevention products, and the development of replicating viral vectors and mRNA. The company was founded in 1996 by Seth Berkley and Lee C. Smith and is headquartered in New York, NY. | Corporate Officer/Principal | 2010-11-29 | - |
Career history of Michèle Barzach
Former positions of Michèle Barzach
| Companies | Position | Start | End |
|---|---|---|---|
| GSK PLC | Director/Board Member | 1996-12-31 | 2004-05-16 |
| Independent Dir/Board Member | 1996-12-31 | 2004-05-16 |
Statistics
International
| United Kingdom | 2 |
| United States | 2 |
Operational
| Director/Board Member | 1 |
| Independent Dir/Board Member | 1 |
| Corporate Officer/Principal | 1 |
Sectoral
| Health Technology | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| GSK PLC | Health Technology |
| Private companies | 1 |
|---|---|
International AIDS Vaccine Initiative, Inc.
International AIDS Vaccine Initiative, Inc. Pharmaceuticals: MajorHealth Technology International AIDS Vaccine Initiative, Inc. researches and develops to prevent HIV infection and AIDS. It researches and develops vaccine candidates, conducts policy analyses, and serves as an advocate for the field with offices in Africa, India, and Europe. The firm's HIV research and development focuses on three strategies: the design of vaccine immunogens capable of inducing specialized proteins known as broadly neutralizing antibodies, the optimization and development of these antibodies as prevention products, and the development of replicating viral vectors and mRNA. The company was founded in 1996 by Seth Berkley and Lee C. Smith and is headquartered in New York, NY. | Health Technology |
- Stock Market
- Insiders
- Michèle Barzach
- Experience
